arrow
J

Jia-Horng Kao

National Taiwan University Hospital
H指数:92
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Risk Factors for Advanced Fibrosis in Pathology‐Proven Steatotic Liver Disease: Emphasis on Nonelder Subjects

病理学证实的脂肪性肝病中晚期肝纤维化的临床危险因素:侧重于非老年受试者

2026-10-200
PRE
Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection

血清高尔基体蛋白73作为慢性丙型肝炎病毒感染中肝纤维化的无创性标志物

2026-10-190
PRE
Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B

慢性乙型肝炎患者接受有限疗程的昔奈西仑治疗后核苷(类)类似物停药的临床结局

2026-09-010
PRE
HBV RNA, HBcrAg, and HBsAg levels at year 6 do not predict HCC risk in patients with cirrhosis on long-term entecavir therapy

HBV RNA、HBcrAg和HBsAg水平在6年时不预测长期恩替卡韦治疗患者的肝硬化患者发生HCC的风险

2026-08-080
PRE
Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort

慢性乙型肝炎核苷 (酸) ide类似物停止后的长期结果-RETRACT-B队列的随访

2026-03-300
OAAI
HCC predictors in routine practice for patients with chronic liver diseases: Correspondence to editorial on High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease

慢性肝病患者的HCC预测因子在常规实践中的应用:对“高SAFE评分可预测病毒性和非病毒性肝炎以及代谢功能障碍相关脂肪性肝病中的肝细胞癌”一文的编者按的回应

2026-01-010
OAAI
Response to Comments on “Comparison of the clinicoradiological features and outcomes of lymphoepithelioma-like cholangiocarcinoma and conventional intrahepatic cholangiocarcinoma: A propensity score matching analysis”

对“淋巴上皮样胆管癌与常规肝内胆管癌的临床影像学特征及预后的比较:一项倾向性评分匹配分析”一文的评论回复

2025-12-120
OAAI
GWAS Study Identifies 3-SNP Risk Variants of PNPLA3/SAMM50 Linked to HCC Development in Individuals with Non-viral Liver Diseases

全基因组关联研究识别出PNPLA3/SAMM50的3个单核苷酸多态性风险变异,这些变异与非病毒性肝病患者中肝细胞癌的发生相关。

2025-11-110
OAAI
Population-specific polygenic risk scores for people of Han Chinese ancestry

汉族人群特异的多基因风险评分

Nature
IF48.5
2025-10-150
OAAI